Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial assessing safety and efficacy of T0903131 (INT131) besylate for type 2 diabetes; the study status is completed.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Phase 3 Alogliptin Pediatric Study [Phase 3]
Phase 3 pediatric study of alogliptin for type 2 diabetes has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial investigating efficacy of mifepristone in males with type 2 diabetes mellitus and insulin resistance; terminated with results …
-
EMA withdrawal · 2022-10-18EMA Withdrawn: Glubrava (metformin hydrochloride;pioglitazone hydrochloride) — Takeda Pharma A/S
Glubrava, a fixed-dose combination of metformin hydrochloride and pioglitazone hydrochloride, has been withdrawn from the market.
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial) [NA]
The MERIT multicenter trial evaluating endoscopic sleeve gastrectomy for obesity-related indications has completed with results posted in 20…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2022-10-17EMA Withdrawn: Glustin (pioglitazone hydrochloride) — Takeda Pharma A/S
EMA has withdrawn Glustin (pioglitazone hydrochloride) from the market.
-
EMA withdrawal · 2022-10-17EMA Withdrawn: Glidipion (previously Pioglitazone Actavis Group) (pioglitazone hydrochloride) — Actavis Group PTC ehf
The EMA has withdrawn Glidipion (pioglitazone hydrochloride) from the market.
-
FDA approval · 2022-10-14FDA Approved: LYUMJEV — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for LYUMJEV (insulin lispro-aabc) from Eli Lilly and Company.
-
FDA approval · 2022-10-13FDA Approved: NATEGLINIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approves a supplemental application for nateglinide by Strides Pharma Science Limited.
-
FDA approval · 2022-10-13FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Invokamet (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2022-10-13FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for a dapagliflozin and metformin hydrochloride combination product from Prasco Laboratories.
-
FDA approval · 2022-10-13FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Glyxambi (empagliflozin and linagliptin) from Boehringer Ingelheim, authorizing an additiona…
-
FDA approval · 2022-10-13FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) to update the product labeling. The app…
-
FDA approval · 2022-10-13FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY XR (empagliflozin/metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, I…
-
FDA approval · 2022-10-13FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approves a supplemental application for STEGLUJAN (ertugliflozin and sitagliptin).
-
FDA approval · 2022-10-13FDA Approved: STEGLATRO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for STEGLATRO (ertugliflozin) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2022-10-13FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)
FDA granted a supplemental approval for Segluromet, the combination of ertugliflozin and metformin hydrochloride, from Merck Sharp & Dohme L…
-
FDA approval · 2022-10-13FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKANA (canagliflozin) submitted by Janssen Pharmaceuticals, Inc.
-
FDA approval · 2022-10-13FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Synjardy (empagliflozin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceutica…
-
FDA approval · 2022-10-13FDA Approved: TRIJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for TRIJARDY XR, a fixed-dose combination of empagliflozin, linagliptin, and metformin hydrochloride…
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes [Phase 3]
Phase 3 trial comparing eplerenone to spironolactone in heart failure patients with glucose intolerance or Type 2 diabetes completed.
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers [NA]
Completed trial assessing the effects of an exercise program on health outcomes in people with diabetic foot ulcers; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Exeantide in Type 2 Diabetes on Insulin [Phase 2]
A Phase 2 trial evaluating Exeantide in patients with Type 2 Diabetes who are on insulin has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin [Phase 3]
A Phase 3 trial comparing ipragliflozin to sitagliptin in adults with uncontrolled type 2 diabetes on sulfonylurea and metformin has complet…
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D [Phase 4]
Phase 4 trial investigating the effects of empagliflozin and dulaglutide on metabolic-associated fatty liver disease in patients with type 2…